Laboratorios Farmacéuticos ROVI S.A. (hereinafter, “ROVI”) has announced that it has received the first regulatory approvals in the United States,...

Letrozole SIE is an investigational medicine to treat hormone receptor-positive breast cancer and is expected to provide sustained and stable...

Both companies cooperate in promoting more sustainable pharmaceutical manufacturing processes while supporting innovation in medicines based on next-generation sustained-release platforms...

Both companies will cooperate in developing customized three-dimensional polymeric scaffolds to encapsulate pancreatic-derived spheroids, and in conducting a feasibility study...

Thanks to LAISOLID, ROVI is advancing in the development of long-acting injectable formulations capable of preserving the stability and efficacy...

With a total investment exceeding 80 million euros, LAISOLID addresses both the development of industrial processes and the creation of...

The LAISOLID project, developed by Laboratorios Farmacéuticos ROVI, has been granted €36.3 million in funding by the Centre for Technological...